These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34134097)

  • 21. Nanoparticle-mediated pulmonary drug delivery: a review.
    Paranjpe M; Müller-Goymann CC
    Int J Mol Sci; 2014 Apr; 15(4):5852-73. PubMed ID: 24717409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral inhalation for delivery of proteins and peptides to the lungs.
    Fröhlich E; Salar-Behzadi S
    Eur J Pharm Biopharm; 2021 Jun; 163():198-211. PubMed ID: 33852968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome(.).
    Aragao-Santiago L; Bohr A; Delaval M; Dalla-Bona AC; Gessler T; Seeger W; Beck-Broichsitter M
    Curr Pharm Des; 2016; 22(9):1147-60. PubMed ID: 26675224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats.
    Haque S; Feeney O; Meeusen E; Boyd BJ; McIntosh MP; Pouton CW; Whittaker M; Kaminskas LM
    J Control Release; 2019 Aug; 307():32-43. PubMed ID: 31152749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery.
    Karathanasis E; Ayyagari AL; Bhavane R; Bellamkonda RV; Annapragada AV
    J Control Release; 2005 Mar; 103(1):159-75. PubMed ID: 15710508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patented therapeutic drug delivery strategies for targeting pulmonary diseases.
    Thakur AK; Chellappan DK; Dua K; Mehta M; Satija S; Singh I
    Expert Opin Ther Pat; 2020 May; 30(5):375-387. PubMed ID: 32178542
    [No Abstract]   [Full Text] [Related]  

  • 27. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects.
    Tahara K; Tomida H; Ito Y; Tachikawa S; Onodera R; Tanaka H; Tozuka Y; Takeuchi H
    Int J Pharm; 2016 May; 505(1-2):139-46. PubMed ID: 27012982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carrier-based strategies for targeting protein and peptide drugs to the lungs.
    Cryan SA
    AAPS J; 2005 Mar; 7(1):E20-41. PubMed ID: 16146340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesoporous silica nanoparticles for pulmonary drug delivery.
    García-Fernández A; Sancenón F; Martínez-Máñez R
    Adv Drug Deliv Rev; 2021 Oct; 177():113953. PubMed ID: 34474094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges.
    Ruge CA; Kirch J; Lehr CM
    Lancet Respir Med; 2013 Jul; 1(5):402-13. PubMed ID: 24429205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposomal formulations for inhalation.
    Cipolla D; Gonda I; Chan HK
    Ther Deliv; 2013 Aug; 4(8):1047-72. PubMed ID: 23919478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the efficacy of inhaled drugs for severe lung diseases: emerging pulmonary delivery strategies.
    Ungaro F; Vanbever R
    Adv Drug Deliv Rev; 2014 Aug; 75():1-2. PubMed ID: 25109852
    [No Abstract]   [Full Text] [Related]  

  • 33. Pulmonary Delivery of Anti-Tubercular Drugs Using Ligand Anchored pH Sensitive Liposomes for the Treatment of Pulmonary Tuberculosis.
    Bhardwaj A; Grobler A; Rath G; Goyal AK; Jain AK; Mehta A
    Curr Drug Deliv; 2016; 13(6):909-22. PubMed ID: 26718489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary delivery systems for polyphenols.
    Trotta V; Scalia S
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1043-1052. PubMed ID: 28276786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into Asymmetric Liposomes as a Potential Intervention for Drug Delivery Including Pulmonary Nanotherapeutics.
    Al Badri YN; Chaw CS; Elkordy AA
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhalable Levofloxacin Liposomes Complemented with Lysozyme for Treatment of Pulmonary Infection in Rats: Effective Antimicrobial and Antibiofilm Strategy.
    Gupta PV; Nirwane AM; Nagarsenker MS
    AAPS PharmSciTech; 2018 Apr; 19(3):1454-1467. PubMed ID: 29464594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal alpha-tocopherol alleviates the progression of paraquat-induced lung damage.
    Suntres ZE; Shek PN
    J Drug Target; 1995; 2(6):493-500. PubMed ID: 7773611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biokinetics of Aerosolized Liposomal Ciclosporin A in Human Lung Cells In Vitro Using an Air-Liquid Cell Interface Exposure System.
    Schmid O; Jud C; Umehara Y; Mueller D; Bucholski A; Gruber F; Denk O; Egle R; Petri-Fink A; Rothen-Rutishauser B
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):411-424. PubMed ID: 28683218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanotechnological Systems and Lung: A Perfect Combination for Lung Pharmaceutical Applications.
    Santonocito D; Puglia C
    Curr Med Chem; 2023; 30(6):725-743. PubMed ID: 36043745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 Apr; 79(5):555-562. PubMed ID: 30877642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.